Business
TETRIS PHARMA ANNOUNCES AGREEMENT WITH GOODLIFE
TETRIS PHARMA ANNOUNCES AGREEMENT WITH GOODLIFE.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n\nArecor Therapeutics plc\n(\"Arecor\" or the \"Group\")\n \nTETRIS PHARMA ANNOUNCES COMMERCIALISATION AGREEMENT WITH GOODLIFE\n \nCambridge, UK, 4 September 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, announces that subsidiary company, Tetris Pharma Ltd has established an exclusive commercialisation agreement with Goodlife, who will act as sole partner for the import, marketing and distribution of Ogluo® in the BeNeLux region.\n \nSee full Tetris Pharma announcement below:\n \nTetris Pharma announces commercialisation agreement with Goodlife\n \nPartnership to drive accelerated market adoption of Ogluo in BeNeLux region\n \n4 September 2023 - Tetris Pharma Ltd (\"Tetris Pharma\" or \"the Company\"), a subsidiary of biopharmaceutical company, Arecor Therapeutics plc (AIM: AREC), today announces that it has established an exclusive commercialisation agreement with Goodlife, who will act as sole partner for the import, marketing and distribution of Ogluo® (glucagon prefilled autoinjector pen) in the BeNeLux region.\n \nThe Zorginstiuut Nederland (the National Healthcare Institute of The Netherlands) has approved Ogluo® at the requested price on List 1B and Goodlife is expected to launch the product in The Netherlands during H1 2024.\n \nSarah Howell, Chief Executive Officer at Arecor, said: \"Goodlife provides the commercial expertise and detailed understanding of regional market dynamics that are essential for the Company's continued roll-out of Ogluo® and its market adoption in the BeNeLux region. The upcoming launch in The Netherlands adds to existing markets in the UK, Germany, Austria, Denmark and Norway, as part of the planned on-going pan-European commercial roll-out for this important product.\"\n \nKoen Perenboom, Managing Director, Goodlife, said: \"With more than a quarter of a million people living with insulin-treated diabetes and at risk of severe hypoglycaemia in The Netherlands, Ogluo is an important treatment option for people with diabetes and their caregivers, that can provide them with the confidence to manage severe hypoglycaemic events. This strategic collaboration with Arecor symbolises our mutual commitment to provide every individual patient excellent care.\"\n \nAbout Ogluo...